Claims
- 1. A method of identifying a compound capable of enhancing or inhibiting binding between Signal Transducer and Activator of Transcription (STAT) protein dimers to each other at an interface domain and/or a nucleic acid binding site, comprising:
(a) obtaining a set of atomic coordinates defining the three dimensional structure of a crystal of an N-terminal fragment of a STAT protein that effectively diffracts X-rays for the determination of the atomic coordinates of the N-terminal fragment to a resolution of 1.45 Å, wherein the N-terminal fragment of a STAT protein comprises amino acid residues 1-130 of SEQ ID NO:1, the crystal has a space group of P6522 and a unit cell of dimensions a=79.51 Å, b=79.51 Å, and c=84.68 Å, and wherein the interface domain is formed such that contact exists between amino acid residues Gln8 (Q8), Ile12 (I12), and Leu15 (L15) of α helices 1 and 2, Met28 (M28) and Glu29 (E29) of α helix 3 of a first STAT protein partner of the dimer, and Leu77 (L77) and Leu78 (L78) in α helix 7 of a second STAT protein partner of the dimer; (b) contacting a test compound with two or more dimeric STAT proteins in the presence of a nucleic acid containing at least two adjacent binding sites for STAT protein dimers; and (c) detecting the effect of the test compound on the binding of the dimeric STAT proteins to each other and/or to the nucleic acid binding site, wherein the test compound is identified as capable of enhancing or inhibiting binding between dimeric STAT proteins when it either enhances or inhibits the binding of dimeric STAT proteins to each other and/or the nucleic acid binding site.
- 2. The method of claim 1, wherein a test compound is a compound designed to bind the interface domain formed between amino acid residues Gln8 (Q8), Ile12 (I12), and Leu15 (L15) of α helices 1 and 2, Met28 (M28) and Glu29 (E29) of α helix 3 of a first STAT protein partner of the dimer, and Leu77 (L77) and Leu78 (L78) in α helix 7 of a second STAT protein partner of the dimer.
- 3. A method of identifying a compound capable of modulating binding between dimeric Signal Transducer and Activator of Transcription (STAT) proteins to each other at an interface domain and/or a nucleic acid binding site, comprising:
(a) obtaining a set of atomic coordinates defining the three dimensional structure of a crystal of an N-terminal fragment of a STAT protein that effectively diffracts X-rays for the determination of the atomic coordinates of the N-terminal fragment to a resolution of 1.45 Å, wherein the N-terminal fragment of a STAT protein comprises amino acid residues 1-130 of SEQ ID NO:1, the crystal has a space group of P6522 and a unit cell of dimensions a=79.51 Å, b=79.51 Å, and c=84.68 Å, and wherein the interface domain is formed such that contact exists between amino acid residues Gln8 (Q8), Ile12 (I12), and Leu15 (L15) of α helices 1 and 2, Met28 (M28) and Glu29 (E29) of α helix 3 of a first STAT protein partner of the dimer, and Leu77 (L77) and Leu78 (L78) in α helix 7 of a second STAT protein partner of the dimer; (b) contacting a test compound with two or more dimeric STAT proteins in the presence of a nucleic acid containing at least two adjacent binding sites for STAT protein dimers; and (c) detecting the effect of the test compound on the binding of the dimeric STAT proteins to each other and/or to the nucleic acid binding site, wherein the test compound is identified as capable of modulating binding between dimeric STAT proteins when the binding of dimeric STAT proteins to each other and/or the nucleic acid binding site is changed in the presence of the test compound compared to binding in the absence of the test compound.
- 4. The method of claim 1, wherein a test compound is a compound designed to bind the interface domain formed between amino acid residues Gln8 (Q8), Ile12 (I12), and Leu15 (L15) of α helices 1 and 2, Met28 (M28) and Glu29 (E29) of α helix 3 of a first STAT protein partner of the dimer, and Leu77 (L77) and Leu78 (L78) in α helix 7 of a second STAT protein partner of the dimer.
- 5. A method for identifying a compound that enhances or diminishes the ability of dimeric Signal Transducer and Activator of Transcription (STAT) proteins to induce the expression of a gene operably under the control of a promoter containing at least two adjacent weak binding sites for STAT protein dimers, comprising:
(a) obtaining a set of atomic coordinates defining the three dimensional structure of a crystal of an N-terminal fragment of a STAT protein that effectively diffracts X-rays for the determination of the atomic coordinates of the N-terminal fragment to a resolution of 1.45 Å, wherein the N-terminal fragment of a STAT protein comprises amino acid residues 1-130 of SEQ ID NO:1, the crystal has a space group of P6522 and a unit cell of dimensions a=79.51 Å, b=79.51 Å, and c=84.68 Å, and wherein the interface domain is formed such that contact exists between amino acid residues Gln8 (Q8), Ile12 (I12), and Leu15 (L15) of α helices 1 and 2, Met28 (M28) and Glu29 (E29) of α helix 3 of a first STAT protein partner of the dimer, and Leu77 (L77) and Leu78 (L78) in α helix 7 of a second STAT protein partner of the dimer; (b) measuring the level of expression of a first reporter gene and a second reporter gene contained by a host cell in the presence and absence of a test compound, wherein the first reporter gene is operably linked to a first promoter containing at least two adjacent weak binding sites for STAT protein dimers, and the second reporter gene is operably linked to a second promoter comprising at least one strong binding site for a STAT protein dimer, and wherein the binding of STAT protein dimers to the two adjacent weak binding sites induces the expression of the first reporter gene, and the binding of the STAT protein dimer to the strong binding site induces the expression of the second reporter gene, and wherein the host cell contains STAT protein dimers; and (c) comparing the level of expression of the first report gene with that of the second reporter gene in the presence and absence of the test compound, wherein when the presence of the test compound results in an increase in the level of expression of the first reporter gene but not that of the second reporter gene, the test compound is identified as a compound that enhances the ability of STAT protein dimers to induce the expression of a gene operably under the control of a promoter containing at least two adjacent weak binding sites for STAT protein dimers, and when the presence of a test compound results in a decrease in the level of expression of the first reporter gene but not that of the second reporter gene, the test compound is identified as a compound that inhibits the ability of STAT protein dimers to induce the expression of a gene operably under the control of a promoter containing at least two adjacent weak binding sites for STAT protein dimers.
- 8. The method of claim 7, wherein a test compound is a compound designed to bind the interface domain formed between amino acid residues Gln8 (Q8), Ile12 (I12), and Leu15 (L15) of α helices 1 and 2, Met28 (M28) and Glu29 (E29) of α helix 3 of a first STAT protein partner of the dimer, and Leu77 (L77) and Leu78 (L78) in α helix 7 of a second STAT protein partner of the dimer.
- 9. The method of claim 7, wherein the host cells is a mammalian cell.
- 10. The method of claim 7, wherein the first reporter gen is contained by a first host cell, and the second reporter gene is contained by a second host cell, and wherein the first and second host cells both contain STAT protein dimers.
- 11. The method of claim 7, wherein the weak STAT binding sites are selected from the group consisting of binding sites present in the regulatory regions of the MIG gene, the c-fos gene, and the interferon-γ gene.
RELATED PATENT APPLICATIONS
[0001] This application is a continuation-in-part and claims priority under 35 USC §120 U.S. Ser. No. 10/045,792 filed Feb. 8, 2002, which is a divisional application of U.S. Ser. No. 09/556,273 filed Apr. 24, 2002, which is a divisional application of U.S. Ser. No. 09/012,710 filed Jan. 23, 1998, now U.S. Pat. No. 6,087,478, which applications are herein specifically incorporated by reference in their entirety.
GOVERNMENT SUPPORT
[0002] The research leading to the present invention was supported, at least in part, by NIH Grant Nos. AI32489 and AI34420. Accordingly, the Government may have certain rights in the invention.
Divisions (2)
|
Number |
Date |
Country |
Parent |
09556273 |
Apr 2000 |
US |
Child |
10045792 |
Oct 2001 |
US |
Parent |
09012710 |
Jan 1998 |
US |
Child |
09556273 |
Apr 2000 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
10045792 |
Oct 2001 |
US |
Child |
10179451 |
Jun 2002 |
US |